Endologix Acquires Pounce™ Thrombectomy System, Expanding Its Vascular Intervention Portfolio

SANTA ROSA, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company focused on advancing innovative therapies for the interventional treatment of vascular disease, today announced the acquisition of the Pounce™ Thrombectomy System from Surmodics, Inc. The transaction closed on May 18, 2026.

The Pounce System is an FDA-cleared, fully mechanical thrombectomy system for the non-surgical removal of thrombi and emboli from peripheral arteries. Built around proprietary dual-basket technology and a nitinol collection funnel, the system is designed to support procedural simplicity, versatility, and efficiency without reliance on capital equipment, thrombolytics, or aspiration. The platform includes multiple commercially available configurations: Pounce LP, Pounce, and Pounce XL, designed to support use across a range of peripheral arterial vessel sizes, including smaller and more distal vessels. The Pounce Thrombectomy System will continue to be marketed in accordance with its existing FDA clearance during a transition period following the acquisition.

"The Pounce Thrombectomy System is a strong strategic and clinical fit for Endologix," said John Liddicoat, M.D., President and Chief Executive Officer of Endologix. "It serves the same physicians and patients we already work with every day and brings a clinically differentiated mechanical approach that complements our vascular intervention portfolio. We are excited to welcome members of the Pounce team as part of our intentional investment in innovation that helps vascular specialists deliver better care."

The acquisition strengthens the Endologix commercial offering for the vascular interventionalists who already partner with the company on its DETOUR®, ALTO™ and AFX®2 platforms. The addition of a clinically differentiated mechanical thrombectomy option enables Endologix to support a broader continuum of care for patients with peripheral vascular disease. A core group of Surmodics team members supporting Pounce will join Endologix as part of the transaction.

“I have used both Pounce and Endologix technologies in my practice, and bringing these solutions together under one organization makes a great deal of clinical sense," said Venkatesh Ramaiah, M.D., FACS, Chief of Vascular and Endovascular Surgery at Pulse Cardiovascular Institute. “The Pounce fully mechanical thrombectomy system offers a grab-and-go solution that does not rely on thrombolytics or aspiration and complements Endologix’s portfolio of vascular technologies for the treatment of peripheral arterial disease. Together, these technologies provide physicians with additional flexibility when addressing thrombi and emboli in the peripheral arterial vasculature.”

For more info on the Pounce Thrombectomy System, visit: https://pouncesystem.com/

About Endologix

Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. Endologix’s commercial products, including the AFX®2 Endovascular AAA System, ALTO® Abdominal Stent Graft System, and the DETOUR™ System, are designed to treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm committed to advancing healthcare through investment, intelligence, and philanthropy. The company has offices and manufacturing sites in Irvine and Santa Rosa, California. To learn more about Endologix, please visit https://endologix.com.